Takeda's £46B Shire Buy Gets Nod From Chinese Regulator
Japanese pharmaceutical giant Takeda announced Friday that Chinese regulators have given their "unconditional clearance" for a planned £46 billion ($60 billion) acquisition of Dublin's Shire, the rare disease-focused drugmaker....To view the full article, register now.
Already a subscriber? Click here to view full article